In the biotech-verse, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is riding a fresh wave of positive momentum following first quarter earnings that outclassed investors’ …
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the first quarter of 2017. “The first quarter of 2017 showed significant progress across all …
Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), as it appears that payors are still actively …
Wells Fargo and Needham are chiming in with mixed takes on biotech companies Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Sarepta Therapeutics Inc (NASDAQ:SRPT). …
Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), reiterating an Outperform rating and price target …
Sarepta Therapeutics Inc (NASDAQ:SRPT) granted equity awards on January 31, 2017, that were previously approved by the Compensation Committee of its Board of …
In a research report published Tuesday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), with a …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced it has entered a research and option agreement with Nationwide Children’s Hospital on their microdystrophin gene therapy program. …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that the European Medicines Agency (EMA) validated the previously submitted Marketing Authorization application (MAA) for eteplirsen to treat …
Cowen analyst Ritu Baral is chiming in with her two cents on Sarepta Therapeutics Inc (NASDAQ:SRPT) as to what the early days of …
